Eiger BioPharmaceuticals (EIGR) Reports Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia
Tweet Send to a Friend
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced positive results from the Phase 2 PREVENT study. PREVENT is a multi-center ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
